ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for severe forms of cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. ERYTECH Pharma S.A. has research collaboration with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is headquartered in Lyon, France.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [01/31/2020 07:38 PST] ERYP Expected to Trade Up After Bullish Patterns Develop
• [01/30/2020 07:42 PST] ERYP Expected to Trade Up After Bullish Patterns Develop
• [01/29/2020 08:09 PST] ERYP Expected to Trade Up After Bullish Patterns Develop
• [01/28/2020 07:30 PST] ERYP Expected to Trade Up After Bullish Patterns Develop
• [01/27/2020 07:47 PST] ERYP Expected to Trade Up After Bullish Patterns Develop
• [01/17/2020 11:07 PST] ERYTECH Pharma S.A. (NASDAQ:ERYP), Up By 100.00% ($7.38) From $7.380 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [01/08/2020 07:49 PST] ERYP Expected to Trade Down After Bearish Patterns Develop
• [01/02/2020 07:39 PST] ERYP Expected to Trade Up After Bullish Patterns Develop
• [12/31/2019 12:23 PST] ERYTECH Pharma S.A. (NASDAQ:ERYP), Up By 100.00% ($6.85) From $6.850 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [12/31/2019 07:45 PST] ERYP Expected to Trade Up After Bullish Patterns Develop